Kadimastem (TASE:KDST)

Executive Summary

Kadimastem is a clinical-stage Israeli biotechnology company developing off-the-shelf cell therapies from its proprietary human embryonic stem cell platform. The company’s lead program, AstroRx, is a glial progenitor cell therapy aimed at slowing disease progression in amyotrophic lateral sclerosis (ALS). AstroRx has completed a Phase 1/2a safety trial and is advancing toward a pivotal study. Kadimastem’s second program, ITOL-102, is a cell therapy consisting of islet-like endocrine cells for the treatment of insulin-dependent diabetes, with the goal of restoring glucose regulation and eliminating the need for exogenous insulin. Both programs leverage scalable, GMP-compliant manufacturing to address large unmet medical needs in neurodegeneration and metabolic disease. Kadimastem is listed on the Tel Aviv Stock Exchange (TASE: KDST) and has made progress in establishing clinical proof-of-concept. The near-term value inflection points include data readouts from AstroRx’s next-stage trial and progress in regulatory filings for ITOL-102. The company faces typical early-stage risks, including capital requirements and clinical execution, but its platform and pipeline position it as a promising player in the regenerative medicine space. With a strong IP estate and a focus on high-impact indications, Kadimastem presents a speculative opportunity for investors seeking exposure to stem cell therapies.

Upcoming Catalysts (preview)

• Q3 2026AstroRx Phase 2 clinical data readout in ALS60% success
• Q4 2026ITOL-102 IND/CTA submission for diabetes70% success
• H2 2026Strategic partnership or non-dilutive funding for GMP manufacturing50% success